YMB YM Bio.'b'ser1

    YM BIOSCIENCES NOTICE OF CONFERENCE CALL TO ANNOUNCE FOURTH QUARTER AND
YEAR-END FISCAL 2007 FINANCIAL RESULTS

    MISSISSAUGA, ON, Sept. 20 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX:
YM, AIM: YMBA), will release its fiscal 2007 financial results on Monday,
September 24, 2007 at 1:00AM (EDT) (6:00AM BST). The announcement will be
followed by a conference call at 9:00AM (EST), hosted by David Allan,
Chairman, CEO & Director of YM BioSciences Inc.

                           CONFERENCE CALL DETAILS
                           -----------------------

    DATE:              Monday, September 24th, 2007

    TIME:              9:00 AM (EDT)

    DIAL IN NUMBER:    416-644 3414 or 1-800-733-7560

    TAPED REPLAY:      416-640-1917 or 1-877-289-8525

    PASSWORD:          21247767 followed by the number sign

    A live audio webcast of the conference call will be available through
www.ymbiosciences.com. Please connect to this website at least 15 minutes
prior to the conference call to ensure adequate time for any software download
that may be needed to hear the webcast. A replay of the webcast will be
available for 90 days starting on September 24th, 2007 at
www.ymbiosciences.com. A replay of the conference call will also be available
by telephone on September 24th, 2007 through October 1st, 2007.

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The Company has
two late-stage products: nimotuzumab, a humanized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR) and is approved in several
countries for treatment of various types of head and neck cancer; and
AeroLEF(TM), a proprietary, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of moderate to
severe pain, including cancer pain.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.


For further information: Thomas Fechtner, the Trout Group LLC, Tel. (212)
477-9007 x 31, Fax (212) 460-9028, Email: tfechtner(at)troutgroup.com; James
Smith, the Equicom Group Inc., Tel. (416) 815-0700 x 229, Fax (416) 815-0080,
Email: jsmith(at)equicomgroup.com; Nominated Adviser, Canaccord Adams Limited,
Ryan Gaffney, Tel. +44 (0)20 7050 6500
(YM. YMI YMBA)

 



END

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024